Please assess the completion status of the following clinical trial:

Trial Title: Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The participant is willing and able to provide written informed consent~* The participant is willing and able to provide appropriate photo identification~* Participants aged 18 to 85~* Participants have been diagnosed with Fanconi Anemia complementation group A~Exclusion Criteria:~* Participants who are pregnant or are nursing~* Participants with a known history of HIV, hepatitis, or other infectious diseases Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Fanconi Anemia (Non-Specific Genotypes) (Type: None): Cohort 1-Fanconi Anemia (Non-Specific Genotypes) (N=4):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A\*Inclusion preference (not required for enrollment into the study): 1)~Participants preferentially have one of the following genotypes:~c3788_3790delTCT, c295 G to T, c3558-3559 insertion of G, or c1115_1118delTTGG~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
- Fanconi Anemia (c3788_3790delTCT) (Type: None): Cohort 2 - Fanconi Anemia (c3788_3790delTCT) (N=1):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A~5. 1 participant must be diagnosed with the following genotype: c3788_3790delTCT~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
- Fanconi Anemia (c295 G to T) (Type: None): Cohort 3 - Fanconi Anemia (c295 G to T) (N=1):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A~5. 1 participant must be diagnosed with the following genotype: c295 G to T~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
- Fanconi Anemia (c3558-3559 insertion of G) (Type: None): Cohort 4 - Fanconi Anemia (c3558-3559 insertion of G) (N=1):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A~5. 1 participant must be diagnosed with the following genotype: c3558-3559 insertion of G~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
- Fanconi Anemia (c1115_1118delTTGG) (Type: None): Cohort 5 - Fanconi Anemia (c1115_1118delTTGG) (N=1):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A~5. 1 participant must be diagnosed with the following genotype: c1115_1118delTTGG~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues